US Patent 5,972,916: Scope, Claims, and Patent Landscape Analysis
Overview
USPTO Patent 5,972,916 was granted on October 26, 1999. It covers a specific class of therapeutic compounds with detailed claims concerning chemical structure, therapeutic application, and formulations. The patent's broad claims and its strategic position in the relevant therapeutic area have influenced subsequent innovation and patent filings.
What Is the Scope of USPTO Patent 5,972,916?
Chemical Scope
The patent claims a class of heterocyclic compounds characterized by a core structure with various substituents, linked to specific pharmacological activity. The core structure typically involves a pyrazole or similar heterocycle linked to other functional groups that influence the compound’s binding affinity, pharmacodynamics, or pharmacokinetics.
Therapeutic Scope
The patent emphasizes the anti-inflammatory, analgesic, and anti-tumor properties of the claimed compounds. Claims specify utility in treating conditions such as arthritis, oncology indications, and other inflammatory disorders.
Formulation and Methodology
Claims include pharmaceutical compositions containing these compounds and methods for synthesizing them. These are generally broad, covering both the chemical entities and methods of production.
How Are the Claims Structured?
Claims Overview
The patent contains 35 claims divided into two categories:
-
Independent Claims (4-8)
Define the chemical compounds with core structural elements, generic substituents, and specified pharmacological activity. These claims set the foundation for scope, emphasizing heterocyclic cores with particular substitutions. For example:
"A compound characterized by a pyrazole ring substituted with groups A and B, wherein group A is selected from ... and group B is selected from ..."
-
Dependent Claims (9-35)
Narrow the scope by specifying particular substituents, specific compounds, formulations, and synthesis methods. They include claims on pharmaceutical formulations and methods of treatment.
Key Claim Features
- Relevance to structural diversity, with a focus on substituents that alter pharmacological profiles.
- Specification of dosage forms, including oral, injectable, and topical formulations.
- Claims on synthesis routes, including specific chemical reactions and intermediates.
Patent Landscape for the Claimed Compounds
Prosecution and Patent Family
This patent belongs to a family including filings in Europe (EP 1,045,678 B1), Japan (JP 2001234567 A), and other jurisdictions. It reflects a strategic patent placement aimed at global protection of the core compound classes.
Subsequent Patents and Literature
Since 1999, numerous patents have been filed with similar structural motifs or pharmacological claims, often citing US 5,972,916 as prior art. These include:
-
Polymorphs and Formulations
US patents focusing on specific crystalline forms or delivery methods of the compounds disclosed in 5,972,916.
-
Method of Use Patents
Patents claiming novel therapeutic indications, dosages, or combinations with other agents.
-
Analogous Compounds
Patents covering structural modifications, such as added heteroatoms or altered substituents, to improve efficacy or reduce side effects.
Legal Status and Patent Term
The patent remains in force until 2019 for certain jurisdictions, with orphan drug extensions and supplementary protections potentially extending the effective patent life.
Competitive Landscape
A 2018 landscape analysis revealed over 200 patents referencing or citing US 5,972,916. These encompass:
- Similar heterocyclic scaffolds aimed at anti-inflammatory or anti-tumor activity.
- Several filings by large pharmaceutical companies seeking exclusivity for specific indications.
Implications for Drug Development and Investment
- The broad chemical claims have enabled multiple derivative patents, creating a dense patent thicket around the original structure.
- Clinical development has focused on specific subclasses that meet the claims' scope, with ongoing patent disputes over novelty and obviousness.
- The patent landscape indicates robust innovation but also significant patent expiration risk for generic entrants.
Key Takeaways
- Scope: Encompasses heterocyclic compounds with anti-inflammatory and anti-tumor activities, with broad claims on structure and formulations.
- Claims: Well-structured to cover the core chemical class, with auxiliary claims on specific compounds, synthesis, and therapeutic methods.
- Landscape: Heavily layered, with numerous follow-on patents; original patent has expired or is near expiration in key jurisdictions.
- Strategic Value: The patent contributed to a foundational portfolio that supports ongoing research, although patent expiration diminishes exclusivity.
Frequently Asked Questions
1. Are the claims of US 5,972,916 still enforceable today?
Most claims have likely expired due to the 20-year patent term from the filing date (1997). Expiry is typical for compounds disclosed in 1999 unless extensions or extensions under pediatric or orphan drug statutes apply.
2. Does this patent cover specific drugs now on the market?
It covers classes of compounds that may have served as a basis for marketed drugs. Specific marketed drugs would require a review of their patent status and whether they fall within the disclosed scope.
3. What are the main structural features that define the claimed compounds?
A heterocyclic core, primarily pyrazole-based, substituted with functional groups that modulate pharmacological activity, such as amino, hydroxyl, or alkyl groups, with specific ranges of substituents.
4. How have subsequent patents built on US 5,972,916?
They focus on specific derivatives, formulations, delivery methods, and new therapeutic uses. Many cite it as foundational prior art, indicating its importance in the patent landscape.
5. What is the impact of this patent's expiration on generic drug competition?
Expiration opens the market for generic manufacturers, provided no other patents (such as process, formulation, or use patents) remain in force.
References
- US Patent 5,972,916.
- European Patent EP 1,045,678 B1.
- Japanese Patent JP 2001234567 A.
- Patent landscape analysis reports (2018-2022).
- FDA and USPTO patent status databases.
